ROI Financial Advisors LLC Sells 675 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

ROI Financial Advisors LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,322 shares of the company’s stock after selling 675 shares during the period. IDEXX Laboratories accounts for approximately 0.9% of ROI Financial Advisors LLC’s investment portfolio, making the stock its 27th largest holding. ROI Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $1,373,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories during the 4th quarter worth $38,000. Crews Bank & Trust purchased a new position in IDEXX Laboratories during the 4th quarter worth $41,000. Finally, BankPlus Trust Department acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $60,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $393.73 on Friday. The firm has a market cap of $31.91 billion, a PE ratio of 36.90, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a twelve month low of $393.50 and a twelve month high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $435.55 and a 200 day moving average price of $440.31.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent analyst reports. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday. Finally, Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.